Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany; Department of Dermatology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Int Immunopharmacol. 2021 Dec;101(Pt A):108220. doi: 10.1016/j.intimp.2021.108220. Epub 2021 Oct 18.
Hepatocellular carcinoma (HCC) is the most common liver neoplasm with high morbidity and mortality. Tumor immunotherapy might be promising adjuvant therapy for HCC after surgery. To better develop HCC immunotherapy, comprehensive understanding of cell-cell interactions between immune effector cells and HCC cells remains crucial.
To review the existing studies to summarize the cell-cell interactions between major immune effector cells and HCC cells providing new data for HCC immunotherapy.
A systematic review was conducted by searching PubMed database covering all papers published in recent five years up to January 2020. The guidelines of the preferred reporting items for systematic reviews were firmly followed.
There are 9 studies researching the interactions between CD8 T lymphocytes and HCC cells and 22 studies researching that between natural killer (NK) cells and HCC cells. Among the 9 studies, 6 studies reported that CD8 T lymphocytes showed cytotoxicity towards HCC cells while 3 studies found CD8 T lymphocytes were impaired by HCC cells. Among the 22 studies, 20 studies presented that NK cells could inhibit HCC cells. Two studies were found to report NK cell dysfunction in HCC.
Based on the systematic analysis, we concluded that CD8 T lymphocytes and NK cells can inhibit HCC cells. While in turn, HCC cells can also result in the dysfunction of those effector cells through various mechanisms. Organoids and direct contact cell co-culture with primary HCC cells and TILs should be the most innovative way to investigate the interactions and develop novel immunotherapy.
肝细胞癌（HCC）是最常见的肝脏肿瘤，发病率和死亡率都很高。肿瘤免疫疗法可能是 HCC 手术后有前途的辅助治疗方法。为了更好地开发 HCC 免疫疗法，全面了解免疫效应细胞与 HCC 细胞之间的细胞-细胞相互作用仍然至关重要。
综述现有研究，总结主要免疫效应细胞与 HCC 细胞之间的细胞-细胞相互作用，为 HCC 免疫治疗提供新的数据。
通过检索 PubMed 数据库，对截至 2020 年 1 月发表的最近五年内的所有论文进行了系统综述。严格遵循系统评价的首选报告项目指南。
有 9 项研究探讨了 CD8 T 淋巴细胞与 HCC 细胞之间的相互作用，22 项研究探讨了自然杀伤（NK）细胞与 HCC 细胞之间的相互作用。在 9 项研究中，有 6 项研究报道 CD8 T 淋巴细胞对 HCC 细胞具有细胞毒性，而有 3 项研究发现 CD8 T 淋巴细胞受到 HCC 细胞的抑制。在 22 项研究中，有 20 项研究表明 NK 细胞可以抑制 HCC 细胞。有两项研究发现 NK 细胞在 HCC 中功能失调。
基于系统分析，我们得出结论，CD8 T 淋巴细胞和 NK 细胞可以抑制 HCC 细胞。而 HCC 细胞也可以通过各种机制导致这些效应细胞功能障碍。类器官和直接接触细胞共培养与原代 HCC 细胞和 TILs 应该是研究相互作用和开发新免疫疗法的最具创新性的方法。
